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Abstract
The COVID-19 pandemic has upended head and neck cancer care delivery in
ways unforeseen and unprecedented. The impact of these changes parallels
other fields in oncology, but is disproportionate due to protective measures
and limitations on potentially aerosolizing procedures and related interven-
tions specific to the upper aerodigestive tract. The moral and professional
dimensions of providing ethically appropriate and consistent care for our
patients in the COVID-19 crisis are considered herein for head and neck oncol-
ogy providers.
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1 | INTRODUCTION
The COVID-19 pandemic continues to evolve and
commandeer all aspects of clinical management.1 The
impact upon head and neck oncologic care might lead
to delayed diagnoses, treatment, and surveillance in a
manner that threatens optimal outcomes and survival for
untold patients.2 How this will directly influence multi-
disciplinary care in widely divergent settings remains
unknown and uncharted.3 Head and neck cancer
providers will be constrained in their ability to provide
vulnerable patients with the attention and care they
require, and will likely experience moral distress when
routine management is all but impossible. These
feelings may be amplified by conflict between a duty to
care for patients and a duty to protect others by avoiding
high-risk exposures. This article is designed to provide a
guide to the ethical issues inherent to care delivery in
the current COVID-19 era.
1.1 | Conflicting duties
One of the major challenges specific to head and neck
cancer during this pandemic involves the significant risk
associated with examination, biopsy, and treatment of
pathology arising in the upper aerodigestive tract. Health
care workers constituted a large percentage of the first
cohort of infected patients. Potential aerosolization of
SARS-CoA-2 virions hinders our ability to conduct rou-
tine management and requires extra resources and time
to perform what before were routine examinations,
endoscopy, biopsy, and surgery. Recent publications echo
and reinforce the related dimensions of infection control,
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safety, and resource stewardship.4 Airway management
represents a discrete consideration in routine, urgent,
and emergent settings, and newly published guides are
also instructive.5 All of these reaffirm the importance
of protecting patients as well as clinical staff from
unnecessary exposure. Indeed, protections of the clinical
workforce and public are fundamental ethical and
professional responsibilities. However, the balance
between our duty to care for patients with our duty to
protect ourselves and our colleagues is not clear.
The American Head and Neck Society has a dynamic
online resource for head and neck oncology providers.6
The American Academy of Otolaryngology - Head and
Neck Surgery Foundation's related position statement
affirms the need to avoid all clinical interactions which
are not urgent/emergent, but “recognizes that ‘time
sensitivity’ and ‘urgency’ are determined by individual
physician judgment and must always take into account
each individual patient's medical condition, social
circumstances, and needs.”7 Other societies have pro-
duced COVID-19-related resources and guidance that
are also informative. The American College of Sur-
geons' dedicated website clarifies the importance of
delaying/deferring nonessential operations, and offers
comprehensive support, including patient-facing mes-
sages which may be valuable to head and neck surgical
oncology practices.8 The Society for Surgical Oncology
recommends that “urgent procedures… should be care-
fully considered for delay on a case-by case basis… and
diagnoses which have equivalent results with radiation
therapy and surgery should be considered for radiation
therapy.”9 The American Society of Clinical Oncology
has general guidance for cancer providers and patients
to avoid in-person encounters whenever possible, but
the organization does not offer guidance specific to
management of specific cancers.10
Although the duty to the patient is a cornerstone of
the medical profession, it should not trump our duty to
care for ourselves and those around us. Head and neck
cancer practitioners should recognize the stress of the
current situation on themselves, practice diligent self-
care, and liberally seek counsel among colleagues, loved
ones, and professionals.
1.2 | Individual vs population interests
It is clear that we need to collectively limit face-to-face
encounters, and do our part to flatten the epidemiological
curve to protect our collective patient populations,
providers, and society at-large. Demonstrably worsened
clinical outcomes among patients with cancer who con-
tract COVID-19 underscore this risk.11 We also know that
delaying head and neck cancer evaluation and manage-
ment will undoubtedly impact oncologic and functional
outcomes, and patients and providers alike will bristle
when facing such postponements.
The principles of medical ethics, broadly speaking,
require us to consider patient preference, maximizing
benefit, minimizing harm, and being deliberative and
fair.12 The challenge of the current COVID-19 pan-
demic is that honoring these principles as resources
becomes scarce or nonexistent will lead to intrinsic
conflict. There will be instances when we cannot
grant specific individual requests or focus on a spe-
cific patient's needs in a manner that supersedes the
obligation to protect populations and to conserve
resources necessary for others. This highlights the
tension between “clinical ethics” and “public health
ethics.”13 The former, which is familiar to most clini-
cians, focuses on the primacy of the doctor-patient
relationship in formulating evidence-based and indi-
vidualized treatment paradigms designed to maximize
the best outcome for a specific patient. In contrast,
public health ethics concentrates on the needs and
interests of populations, even if that might negatively
impact specific individuals.
Such a paradigm shift might be difficult for individual
head and neck cancer providers to accept, and explains
the intense challenges facing us all. When we shift from
a clinical ethics framework to a public health framework,
it is important that we do not force individual clinicians
to ration at the bedside, but rather, institutions that are
charged with caring for communities must take the lead.
Our oncology community will need to discern when the
needs of populations outweigh the needs of individuals,
potentially leading to treatment delays or nonstandard
treatment paradigms.
Since surgical manipulation of the upper aerodigestive
tract now poses new risks and requires additional
resources, the weighting of treatment choices will change.
Specifically, when nonsurgical modalities are superior to
surgery, the choice is easy. In cases in which these choices
are either neutral or preference-sensitive, nonsurgical
approaches should be recommended. However, for condi-
tions in which surgery is clearly preferred or is the sole
option, proceeding with an operation might carry consid-
erably more risks and tradeoffs than in the pre-COVID-19
era. Relative urgency related to estimated tumor pro-
gression and risk of delay is another metric for triage.
This is not to state that such tradeoffs cannot be justi-
fied, but rather than clinicians will need to recognize
that choices for individual patients will be made based
upon the needs of others in ways we do not normally
consider. Complicating the situation, we will also need
to factor in the finite availability of nonsurgical
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resources and the limited number of skilled personnel
necessary to deliver the selected care safely and appro-
priately. Nonsurgical modalities also require repeated
and uninterrupted visits over extended periods of time
that serve as a potential vector to other populations of
clinical staff and oncology patients seeking similar non-
surgical therapies.
This does not obviate our ethical responsibility to
our patients, though. Even though we might not be
able to provide the same level of care or be able to see
patients face to face, this does not prevent us from
maintaining productive doctor-patient relationships.
Patients and survivors are often intensely vulnerable
and they deserve support, counseling, and reassurance
for cancer control and symptom management as much
as ever. Utilization of virtual care can be invaluable to
counsel our patients and ensure they do not feel
abandoned.14
1.3 | Consistency as an ethical tenet
The multidisciplinary nature of head and neck cancer
care is both an advantage and vulnerability in the
COVID-19 era. Multiple treatment paradigms and the
networks of clinicians create systemic redundancy and
options, all of which are welcome. However, this also
can create conflicting, disparate perspectives, and
approaches, both at societal/national levels and for
individual care teams.
Major ethical concerns arise when dissimilar treatment
approaches are offered to similar groups in different loca-
tions. Even if a provider or group is consistent in their
practice and treatment algorithms for a specific, discrete
population of patients, other providers might employ con-
sistent but fundamentally different approaches, thus creat-
ing different care approaches that are inconsistent with
ethical principles of justice and fairness.
The solution to this dilemma is to ensure consistent
evidence-based approaches as best as possible, consider-
ing the systematic issues. Within our sphere of influence,
it is essential that we form consensus approaches to head
and neck cancer management. Also, given that resource
allocation and safety will impact care decisions, these
best consensus approaches may require revision. At the
institutional level, this requires providers to collaborate
and consider how best to maintain care paradigms. For
example, it would be inappropriate for individual sur-
geons to decide to operate on all oropharyngeal cancers
without proactively unifying the broad approach with
radiation and medical oncology colleagues, whether they
are part of the same institution or part of a broader
referral network. Individual patients can and should still
be discussed in multidisciplinary tumor boards, but this
does not replace a more cogent and cohesive approach to
disease management.
Limited capacity for treatment (regardless of modal-
ity) will also impact decisions. Scarce resource allocation
with regard to ventilators and ICU beds for patients with
COVID-19 is in the spotlight, but the principles similarly
apply to cancer care resources if and when they are also
insufficient.15 The selection of ablative and reconstructive
procedures that avoid the use of ICU beds is an example.
In short, this requires explicit, consistent, evidence-based
and objective standards, transparency, and involvement
of all necessary stakeholders. Such protocols must
responsibly utilize and preserve vital resources, and
frame treatment that aligns as much as possible with
current best practice.
Some populations have been victims of cultural,
racial, geographic, and economic discrimination for
generations and societal stress points such as pandemics
can worsen both explicit and implicit biases.16 Health
care providers must deliberately partner with underrepre-
sented groups to assure that the risks of care disparities
are minimized in the face of crisis.
1.4 | Clinical research
Clinical oncology research trials in the era of COVID-19
can continue in some instances and ethical guidance is
available.17 Trials can be stratified by trial phase, disease
site/stage/histology, and treatment intent as well as how
these options would compare with clinical care off-trial.
Trials with a high likelihood of benefit should proceed
although they may need modification after consideration
of the added burdens, risks, and trial-specific testing and
face-to-face interactions. For trials without clear benefits
to the participant, continued enrollment into the trial is
viewed in the context of the potential for generalizable
knowledge afforded by the data generated. For head and
neck cancer specifically—in everything from investigator-
initiated to cooperative trials—risks, benefits, and tradeoffs
should be assessed, knowing that every intervention and
instrumentation of the upper aerodigestive tract poses a
risk to patients, subjects, and providers alike.
Regulatory and funding agencies have provided
resources to assist. The National Cancer Institute has
issued specific guidance for federally funded cancer
trials,18 and the National Institutes of Health has broader
resources available for clinical researchers.19 In addition,
specific FDA guidance will be of value for those trials
involving their regulatory oversight.20
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2 | CONCLUSION
In summary, COVID-19 threatens the very essence of
head and neck cancer care delivery and puts both
patients and providers at significant risk for additional
foreseen and unforeseen morbidities and mortality. This
creates a significant and previously unknown barrier to
care that must be acknowledged and addressed as an eth-
ical challenge, both as we care for individuals and fulfill
our responsibilities to society. The importance of open
and honest communication, consistent multidisciplinary
planning and messaging, and adoption of novel treat-
ment approaches will be essential.
The practice of head and neck oncology has always
been shaped by disease factors and the complex context
in which our patients require care. Collectively, our
diverse community can and will meet these new travails
with the alacrity, creativity, and commitment for which
we pride ourselves.
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